EGFR and neoplasm: It can be seen that 10 out of 12 NSCLC surgical tumor samples with EGFR-activating mutations (L858R or 19del) were correctly identified as positive by EGFR(+)HX103(+) with a sensitivity of 83.3% (95% CI = 51.6%–97.9%), while 2 of the 11 EGFR wild-type samples were misdiagnosed to EGFR-activating mutations (Fig. 5b).